[en] From March 1981 to January 1984, 116 patients with advanced non-small-cell carcinoma of the lung (NSCCL) were randomly assigned to 3 combinations as follow: CDDP+DVA, CDDP+VP16 and DXR+CTX. 94 patients were evaluable for response, 106 for toxicity and survival. Of 31 patients, 15 (48%; 3 CRs and 12 PRs) responded to CDDP+DVA; of 33 patients, 12 (36%, 2 CRs and 10 PRs) responded to CDDP+VP16: OF 30 patients, 3 (10%) obtained a PR with DXR+CTX (CDDP+DVA vs DXR+CTX, P<0.005; CDDP+VP16 vs DXR+CTX, P<0.05; CDDP+DVA vs CDDP+VP16, P=NS). The median duration of response was 22 weeks in the CDDP-DVA group, 17 weeks in the CDDP-VP16 group, and 16 weeks in the DXR+CTX group. No significant difference in survival was observed among the 3 groups (median: 43, 47, 41 weeks, respectively). Hematologic and neurologic toxicites were significantly higher in the DVA-containing regimen. Despite the lack of improvement of overall survival with the CDDP-containing combinations over the DXR+CTX control group, the good response rate makes them suitable to be used in combined therapeutic strategies